Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer

被引：1
|
作者：
Cheng, Ying
Han, Liang
Wu, Lin
Chen, Jun
Sun, Hongmei
Wen, Guilan
Ji, Yinghua
Zimina, Anastasia
Shi, Jianhua
Pan, Zhijie
Shi, Jinsheng
Wang, Xicheng
Yang, Fang
Yang, Xinyi
Chen, Mengkai
Zhong, Shiqi
Wang, Qingyu
Li, Jing
Cheng, Jiancheng
Ling, Chen
Shan, Yongqiang
Zhu, Jun
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6390
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6390
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005)
    Cheng, Y.
    Han, L.
    Wu, L.
    Chen, J.
    Sun, H.
    Wen, G.
    Ji, Y.
    Dvorkin, M.
    Shi, J.
    Pan, Z.
    Shi, J.
    Wang, X.
    Bai, Y.
    Melkadze, T.
    Pan, Y.
    Min, X.
    Viguro, M.
    Kang, W.
    Wang, Q.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1562 - S1562
  • [2] Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial
    Cheng, Ying
    Han, Liang
    Wu, Lin
    Chen, Jun
    Sun, Hongmei
    Wen, Guilan
    Ji, Yinghua
    Dvorkin, Mikhail
    Shi, Jianhua
    Pan, Zhijie
    Shi, Jinsheng
    Wang, Xicheng
    Bai, Yuansong
    Melkadze, Tamar
    Pan, Yueyin
    Min, Xuhong
    Viguro, Maksym
    Li, Xingya
    Zhao, Yanqiu
    Yang, Junquan
    Makharadze, Tamta
    Arkania, Ekaterine
    Kang, Wenying
    Wang, Qingyu
    Zhu, Jun
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (12): : 1223 - 1232
  • [3] Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.
    Cheng, Ying
    Han, Liang
    Wu, Lin
    Chen, Jun
    Sun, Hongmei
    Wen, Guilan
    Ji, Yinghua
    Zimina, Anastasia V.
    Shi, Jianhua
    Pan, Zhijie
    Shi, Jinsheng
    Wang, Xicheng
    Bai, Yuansong
    Melkadze, Tamar
    Pan, Yueyin
    Min, Xuhong
    Viguro, Maksym
    Li, Jing
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Real-World First-Line Serplulimab-Based Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: The Multicenter ASTRUM-005R Study
    Wu, L.
    Hu, C.
    Su, W.
    Yu, Y.
    Hong, W.
    Liu, Z.
    Su, H.
    Liu, Z.
    Wang, C.
    Pu, Q.
    Guo, H.
    Min, X.
    Chen, Y.
    Zhu, H.
    Luo, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S209 - S209
  • [5] Real-world first-line serplulimab-based immunochemotherapy for extensive-stage small cell lung cancer: The multicenter ASTRUM-005R study.
    Wu, Lin
    Hu, ChengPing
    Su, Wenzhong
    Yu, Yan
    Hong, Wei
    Liu, Zhigang
    Su, Haichuan
    Liu, Zhentian
    Wang, Caixia
    Pu, Qing
    Guo, Hui, Sr.
    Min, Xuhong
    Chen, Yifei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer
    Zheng, Zhiwei
    Chen, Hongcai
    Cai, Hongfu
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [7] Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Qin, Qun
    Zhu, Hong
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [8] ATEZOLIZUMAB PLUS CHEMOTHERAPY IN EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
    Dominguez, L.
    Madronal, Carrion, I
    Rodriguez, Marcos J. A.
    Valera-Rubio, M.
    VALUE IN HEALTH, 2023, 26 (12) : S17 - S17
  • [9] Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
    Nogami, Naoyuki
    Tokito, Takaaki
    Zenke, Yoshitaka
    Satouchi, Miyako
    Seto, Takashi
    Saka, Hideo
    Ohtani, Junko
    Han, Shirong
    Noguchi, Kazuo
    Nishio, Makoto
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (01) : 136 - 144
  • [10] Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Li, Yan
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
12345